Results 11 to 20 of about 20,820 (198)

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. [PDF]

, 2016
ObjectivePreexposure prophylaxis (PrEP) offers a promising new approach to HIV prevention. This systematic review and meta-analysis evaluated the evidence for use of oral PrEP containing tenofovir disoproxil fumarate as an additional HIV prevention ...
Baggaley, Rachel, Dalglish, Sarah L, Fonner, Virginia A, Grant, Robert M, Hodges-Mameletzis, Ioannis, Kennedy, Caitlin E, Koechlin, Florence M, O'Reilly, Kevin R, Rodolph, Michelle   +8 more
core   +5 more sources

Method development and validation for multi-component analysis of lamivudine & tenofovir disoproxil fumarate in bulk drug by UV-visible spectrophotometer & RP-HPLC

Journal of Applied Pharmaceutical Research, 2020
A novel, simple, precise and accurate method developed for the estimation of Lamivudine and tenofovir disoproxil fumarate (TDF) in bulk drug form has been established. Lamivudine and tenofovir are well known drugs and used in treatment of HIV- Ⅰ.
Shweta Sharma, Amar Deep Ankalgi, Pooja Kaushal, M. S. Ashawat   +3 more
doaj   +1 more source

Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review

Revista Paulista de Pediatria, 2023
Objective: To investigate the impact of tenofovir disoproxil fumarate on bone mineral density and bone mineral content in children and adolescents infected with the human immunodeficiency virus.
Maria Brennda Ferreira de Gusmão, Vinícius Vital de Oliveira, Natália Maria da Silva Santos, Luciana Costa Melo   +3 more
doaj   +1 more source

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment. [PDF]

Aliment Pharmacol Ther
In East Asian patients with chronic hepatitis B, rates of virologic suppression through 5 years were high in those treated continuously with tenofovir alafenamide (TAF) and in those switched from tenofovir disoproxil fumarate (TDF) to TAF. Improved renal and bone safety was observed in patients switching from TDF to TAF.
Wong GL, Gane E, Pan CQ, Fung S, Ma MM, Izumi N, Shalimar, Lim SG, Chuang WL, Mehta R, Lim YS, Yee LJ, Flaherty JF, Abramov F, Wang H, Buti M.   +15 more
europepmc   +2 more sources

Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method

Future Journal of Pharmaceutical Sciences, 2021
Background An easy, defined, rapid, and accurate reverse phase high-performance liquid chromatography method was developed and subsequently validated for the concurrent estimation of lamivudine, efavirenz, and tenofovir disoproxil fumarate in their pure ...
Ramreddy Godela, Vijayalaxmi Kammari, Sowjanya Gummadi, Durgaprasad Beda   +3 more
doaj   +1 more source

Evaluation of genotoxic activity of tenofovir disoproxil fumarate in human peripheral lymphocytes

Çukurova Üniversitesi Tıp Fakültesi Dergisi, 2016
Purpose: Antiretroviral drugs used in the treatment of HIV (Human Immunodeficiency Virus) iinfection, treat by preventing the proliferation of HIV in human body.
Kubra Kurt, Lale Donbak, Ahmet Kayraldiz
doaj   +1 more source

Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. [PDF]

, 2017
BackgroundThe antiretroviral medication, tenofovir disoproxil fumarate (TDF), is used by most human immunodeficiency virus-infected persons in the United States despite higher risks of chronic kidney disease.
Chen, Ruijun, Estrella, Michelle M, Grunfeld, Carl, Horberg, Michael A, Hsue, Priscilla Y, Jotwani, Vasantha, Scherzer, Rebecca, Shlipak, Michael G   +7 more
core   +1 more source

Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring [PDF]

, 2018
Objectives: The resistance profiles of patients receiving long-term ART in sub-Saharan Africa have been poorly described. This study obtained a sensitive assessment of the resistance patterns associated with long-term tenofovir-based ART in a ...
Appiah, Lambert T, Beloukas, Apostolos, Chadwick, David, Geretti, Anna Maria, Phillips, Richard O, Ruggiero, Alessandra, Sarfo, Fred S, Smith, Colette, Stockdale, Alexander J, Villa, Giovanni   +9 more
core   +3 more sources

Efficacy and safety of Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B with High Baseline Viral Load

SVU - International Journal of Medical Sciences, 2020
Background: Chronic hepatitis B virus infection is an important cause of morbidity and mortality. Tenofovir disoproxil fumarate was licensed for the treatment of hepatitis B virus infection. So, the current study aimed to Evaluate efficacy and outcome of
Ahmed Gad Mohamed Ahmed*, Ali Abdel Rahman Sayed Ghweil, Hasan Sedeek Mahmoud   +2 more
doaj   +1 more source

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic ...
Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brown, Kimberley, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, Cunningham, Douglas, de Vente, J, De Wit, S, De Wit, Stéphane, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Eron, Joseph J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girardy, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Hufkens, Veerle, Huhn, G, Iribarren, JA, Jain, M, Jezorwski, John, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lathouwers, Erkki, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Opsomer, Magda, Orkin, C, Orkin, Chloe, Osiyemi, O, Perez-Valero, I, Petrovic, Romana, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Post, Frank A, Prelutsky, D, Pulido, F, Pulido, Federico, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Santos Gil, I, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, Linos, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y   +118 more
core   +2 more sources